Mrs Maureen Coleman BSc
Mrs Coleman has amassed over 30 years’ experience within the pharmaceutical industry, latterly as VP Global Strategy Development for GlaxoSmithKline. Since 2007 she has been working with a number of investor-backed companies including as founding Chief Executive of NovaThera, a regenerative medicine spin-out from Imperial College London, and as Non-Executive Director and Chairman of life science spin-out companies from Oxford, Kings College Universities and other life science entrepreneurs.
Mrs Coleman is currently Chairman of Parafricta Ltd, a wound care specialist materials company, and CN Bio Innovations – the human organ-on-a-chip technology company whose LiverChip and Quantum B® human liver models are being well received as a disruptive route to liver modelling for Hepatitis B drug discovery and ADME tox testing. She is a founding Director of MedInnovate Ltd, a technology consultancy spanning the healthcare industry, and a founding industry consulting partner at Kinapse Ltd. (She brings a wealth of sector relevant knowledge and experienced leadership in developing early stage life science businesses and Big Pharma.)
CHIEF EXECUTIVE OFFICER
Dr Emma Sceats MSc, MS, DPhil
Dr Emma Sceats obtained a DPhil in Chemistry from Oxford University after graduating from the Massachusetts Institute of Technology in 2004 (M.S. Chemistry). She spent three years at Isis Innovation, Oxford’s technology transfer company, managing and licensing a diverse portfolio of IP and software developed at the University. Amongst more than 50 of her projects encryption software that prevents so-called “man-in-the-middle” attacks, conceived and developed at Oxford with US military funding, is now the subject of a successful spin-out with offices in London and San Francisco focusing on secure data transmission and payment protocols.
Dr Sceats joined CN Bio Innovations in 2010 as Commercial Manager to spearhead the organisation’s sales, marketing and business development activities. She has led sales and partnering initiatives with major pharmaceutical organisations and overseen academic research and licensing programs, including with the Massachusetts Institute of Technology (MIT) that have led to the development of the company’s leading technologies and IP. She assumed the role of CEO in January 2016.
CHIEF TECHNOLOGY OFFICER
Dr David Hughes MEng, DPhil
Dr Hughes joined CN Bio Innovations in 2010 as Head of Engineering and was promoted to Technical Director in 2013 with responsibility for the management of all in-house and collaborative research and development programmes and the contract research services business. During his career at CN Bio, he has secured and overseen the successful delivery of government and pharmaceutical research contracts and research grants totalling more than £2Mi.
Dr Hughes was promoted to Chief Technology Officer in July 2014 with responsibility for managing the technical programs with the company’s academic and industrial partners. Dr Hughes is also Principle Investigator on a $26Mi US Defence Advanced Research Projects Agency (DARPA) contract towards development of human in vitro multi-organ platforms and leads a €4Mi EU FP7 program aimed at developing stem cell derived models of human liver. Before joining CN Bio, he spent three years working in manufacturing and research and development at GlaxoSmithKline. Dr Hughes graduated from the University of Oxford with a Masters in Engineering Science and Doctorate in Chemical Engineering.
Dr David Scales PhD LLM FRCPath
Dr Scales has broad experience in the pharmaceutical, biotech and contract research sectors in senior and non-executive roles. During more than 20 years working for large pharmaceutical companies, Dr Scales’ roles included International VP at GlaxoWellcome overseeing development staff located in the USA, UK, Italy and Japan. During his tenure at GlaxoWellcome he represented the European pharmaceutical Industry and chaired the Safety Committee for the first two International Conferences on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
Dr Scales moved into the biotechnology sector in 2000 working as R&D director for Strakan Ltd, Charterhouse Therapeutics Ltd and Antisoma PLC before becoming CEO of Cerogenix Ltd and then GlycoForm Ltd. In January 2013 he joined CN Bio Innovations as Chief Executive before moving on to take a role as a Board Advisor to the company in 2016. Dr Scales initially trained as a toxicological pathologist, holds three degrees from London University and the Royal Postgraduate Medical School, and is a Fellow of the Royal College of Pathologists.